Moleculin Biotech Inc Total Assets
Moleculin Biotech Inc total assets. Based on the latest financial reports, Moleculin Biotech Inc (MBRX) holds total assets worth $22.13 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Moleculin Biotech Inc (MBRX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Moleculin Biotech Inc (2015–2025)
Total assets of Moleculin Biotech Inc from 2015 to 2025. This chart illustrates how Moleculin Biotech Inc's total assets have evolved over time, based on quarterly financial data. See MBRX stock price for real-time trading data and today's change.
Moleculin Biotech Inc - Asset Composition Analysis
Moleculin Biotech Inc Total Assets Breakdown (December 2025)
Moleculin Biotech Inc total assets breakdown as of December 2025. Moleculin Biotech Inc's total assets of $22.13 Million consist of 43.8% current assets and 56.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.1% |
| Accounts Receivable | $7.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.15 Million | 50.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Moleculin Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Moleculin Biotech Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Moleculin Biotech Inc's current assets represent 43.8% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2025, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 50.4% of total assets.
Moleculin Biotech Inc Competitors by Total Assets
Key competitors of Moleculin Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Moleculin Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 0.97 | 19.23 |
| Quick Ratio | 1.41 | 0.97 | 19.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.83 Million | $-165.00K | $83.44 Million |
Moleculin Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Moleculin Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 30.7% |
| Total Assets | $22.13 Million |
| Market Capitalization | $13.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Moleculin Biotech Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Moleculin Biotech Inc's assets grew by 30.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Moleculin Biotech Inc (2015–2025)
The table below shows the annual total assets of Moleculin Biotech Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.13 Million | +30.73% |
| 2024-12-31 | $16.93 Million | -55.71% |
| 2023-12-31 | $38.22 Million | -33.45% |
| 2022-12-31 | $57.42 Million | -31.71% |
| 2021-12-31 | $84.09 Million | +188.37% |
| 2020-12-31 | $29.16 Million | +15.55% |
| 2019-12-31 | $25.23 Million | +28.85% |
| 2018-12-31 | $19.59 Million | +0.52% |
| 2017-12-31 | $19.48 Million | +18.85% |
| 2016-12-31 | $16.39 Million | +58256.54% |
| 2015-12-31 | $28.09K | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more